

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LC Fund VI, L.P.</u>  (Last) (First) (Middle) 10F, TOWER A, RAYCOM INFOTECH PARK NO. 2 KEXUEYUAN SOUTH ROAD  (Street) ZHONGGUANCUN, F4 100190 BEIJING  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/21/2018	3. Issuer Name and Ticker or Trading Symbol <u>BioNano Genomics, Inc</u> [ BNGO ]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	-------------------------------------------------------	----------------------------------------------------------	-------------------------------------------------------

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series C Convertible Preferred Stock	(I)	(I)	Common Stock	8,545,184	0.00	I	By entities affiliated with LC Fund VI, L.P. <sup>(2)</sup>
Series D Convertible Preferred Stock	(I)	(I)	Common Stock	6,443,565	0.00	I	By entities affiliated with LC Fund VI, L.P. <sup>(3)</sup>
Series D-1 Convertible Preferred Stock	(I)	(I)	Common Stock	27,305,708	0.00	I	By entities affiliated with LC Fund VI, L.P. <sup>(4)</sup>
Series D Convertible Preferred Stock Warrants (Right to Buy)	03/04/2016	03/04/2026	Series D Convertible Preferred Stock	11,263,624	0.41	I	By entities affiliated with LC Fund VI, L.P. <sup>(5)</sup>

1. Name and Address of Reporting Person\*  
LC Fund VI, L.P.  
 (Last) (First) (Middle)  
 10F, TOWER A, RAYCOM INFOTECH PARK  
 NO. 2 KEXUEYUAN SOUTH ROAD  
 (Street)  
 ZHONGGUANCUN, F4 100190  
 BEIJING  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
LC Healthcare Fund I, L.P.  
 (Last) (First) (Middle)  
 10F, TOWER A, RAYCOM INFOTECH PARK, NO.  
 KEXUEYUAN SOUTH ROAD  
 (Street)

ZHONGGUANCUN, F4 100190  
BEIJING

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

LC Parallel Fund VI, L.P.

(Last) (First) (Middle)

10F, TOWER A, RAYCOM INFOTECH PARK, NO.  
KEXUEYUAN SOUTH ROAD

(Street)

ZHONGGUANCUN, F4 100190  
BEIJING

(City) (State) (Zip)

**Explanation of Responses:**

1. The convertible preferred stock is convertible at any time at the holder's election and automatically converts upon the consummation of a qualified public offering of the registrant. There is no expiration date for any series of preferred stock.
2. The shares are held as follows: 8,203,376 shares held by LC Fund VI, L.P. ("LC Fund") and 341,808 shares held by LC Parallel Fund VI, L.P. ("Parallel Fund") LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company.
3. The shares are held as follows: 6,143,224 shares held by LC Fund and 300,341 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company.
4. The shares are held as follows: 3,924,722 shares held by LC Fund, 241,948 shares held by Parallel Fund and 23,139,038 shares held by LC Healthcare Fund I, L.P. ("Healthcare Fund"). LC Fund, Parallel Fund and Healthcare Fund are controlled and managed by Legend Capital, a limited liability Chinese company ("Legend Capital"). The Reporting Person is ultimately controlled and managed by Legend Capital.
5. The warrants are held as follows: warrant to purchase 10,738,615 shares held by LC Fund and warrant to purchase 525,009 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company.

**Remarks:**

/s/ Heather Adams, Attorney- 08/21/2018  
in-fact

/s/ Heather Adams, Attorney- 08/21/2018  
in-fact

/s/ Heather Adams, Attorney- 08/21/2018  
in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all, by these presents, that the undersigned hereby constitutes and appoints each of R. Erik Holmlin, Michael Ward and Heather Adams, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of BioNano Genomics, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of July, 2018.

LC Fund IV, L.P.

LC Parallel Fund VI, L.P.

LC Healthcare Fund I, L.P.

/s/ Junfeng Wang